A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer

Summary

This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer

Timeline

Start

2018-12-21

Primary completion

2024-11-29

Completion

2027-02-26

Publications

• Schmid P, Im SA, Nowecki Z, Wysocki PJ, Jassem J, Jung KH, Lord S, Armstrong J, Stewart R, Vukovic P, Denduluri N, Park YH. First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial. Nat Cancer. 2026 Jun;7(6):983-992. doi: 10.1038/s43018-026-01181-8. Epub 2026 Jun 8.

Drugs

Indications